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ABSTRACT Protozoan parasites, including the apicomplexan pathogens Plasmodium
falciparum (which causes malaria) and Toxoplasma gondii (which causes toxoplasmo-
sis), infect millions of people worldwide and represent major human disease bur-
dens. Despite their prevalence, therapeutic strategies to treat infections caused by
these parasites remain limited and are threatened by the emergence of drug resis-
tance, highlighting the need for the identification of novel drug targets. Recently,
homologues of the core autophagy proteins, including Atg8 and Atg3, were identi-
fied in many protozoan parasites. Importantly, components of the Atg8 conjugation
system that facilitate the lipidation of Atg8 are required for both canonical and
parasite-specific functions and are essential for parasite viability. Structural character-
ization of the P. falciparum Atg3-Atg8 (PfAtg3-Atg8) interaction has led to the identi-
fication of compounds that block this interaction. Additionally, many of these com-
pounds inhibit P. falciparum growth in vitro, demonstrating the viability of this
pathway as a drug target. Given the essential role of the Atg8 lipidation pathway in
Toxoplasma, we sought to determine whether three PfAtg3-Atg8 interaction inhibi-
tors identified in the Medicines for Malaria Venture Malaria Box exerted a similar in-
hibitory effect in Toxoplasma. While all three inhibitors blocked Toxoplasma replica-
tion in vitro at submicromolar concentrations, they did not inhibit T. gondii Atg8
(TgAtg8) lipidation. Rather, high concentrations of two of these compounds induced
TgAtg8 lipidation and fragmentation of the parasite mitochondrion, similar to the ef-
fects seen following starvation and monensin-induced autophagy. Additionally, we
report that one of the PfAtg3-Atg8 interaction inhibitors induces Toxoplasma egress
and provide evidence that this is mediated by an increase in intracellular calcium in
response to drug treatment.
KEYWORDS parasites, Plasmodium, Toxoplasma, antiparasitic agents, apicomplexan
parasites, autophagy
In eukaryotic cells, macroautophagy (referred to here as autophagy) is a catabolicprocess wherein cytoplasm components are engulfed by an elongating membrane
structure referred to as the phagophore. This vesicle matures into an enclosed, dual-
membrane vesicle, termed the autophagosome, and is trafficked to the lysosome/
vacuole for degradation of the engulfed material (1). This process is induced in
response to nutrient starvation (2, 3) but also plays a significant role in cellular
development and differentiation (4), proteostasis (5), and clearance of damaged organ-
elles and as a defense mechanism against invading pathogens (6, 7). While over 30
autophagy-related (ATG) genes have been identified in Saccharomyces cerevisiae and
mammalian systems, a subset of these genes comprises the core autophagy
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machinery. These core ATG genes are required for de novo autophagosome formation
(8) and are especially well conserved across eukaryotes.
Approximately half of the core autophagy proteins are directly or indirectly involved
in facilitating the conjugation of the cytosolic ubiquitin-like protein Atg8 (LC3/
GABARAP in mammals) to phosphatidylethanolamine (PE), which recruits Atg8 to the
phagophore membrane. During autophagosome biogenesis, Atg8 is critical for elon-
gation and fusion of the phagophore membrane. Atg8 can also bind with substrate and
adapter proteins containing the Atg8-interacting motif (AIM) to selectively recruit
proteins to the autophagosome for degradation (9, 10). Conjugation of Atg8 to PE is
carried out via the E1-like enzyme Atg7 and the E2-like enzyme Atg3, with the
oligomeric Atg5-Atg12-Atg16 complex providing E3-like enzymatic function to stimu-
late the transfer of Atg8 from Atg3 to PE (11). Additionally, the cysteine proteinase Atg4
is responsible both for preprocessing of Atg8 to expose the C-terminal glycine for
lipidation and for cleavage of the amide bond between Atg8 and PE to liberate Atg8
from the autophagosome outer membrane during autophagosome maturation (11, 12).
Recently, a conserved subset of the autophagy machinery has been identified in
multiple species of early-branching eukaryotic pathogens (13). While homologues of
many ATG genes are either highly divergent or completely absent, the Atg8 conjuga-
tion machinery is well conserved in many protozoans. Characterization of the compo-
nents of the Atg8 conjugation machinery in the apicomplexan parasites Plasmodium
spp. and Toxoplasma gondii revealed that this pathway is functionally conserved and
essential for survival (14–16). In Toxoplasma, Atg8 lipidation is induced in response to
starvation or drug treatment, as visualized by the formation of Atg8-containing double-
membrane vesicles and/or green fluorescent protein (GFP)-T. gondii Atg8 (TgAtg8)
punctae that resemble putative autophagosomes (14, 17). Although autophagy may be
induced to allow the parasite to mitigate potentially harmful environmental stresses,
prolonged exposure to autophagy-inducing stressors results in a loss of parasite
viability with features resembling an autophagy-like cell death process (17, 18). None-
theless, Atg8 also has unique functions beyond autophagy in apicomplexan parasites.
Atg8 homologues in Plasmodium and Toxoplasma localize to the outer membrane of
the apicoplast (14, 19, 20), a nonphotosynthetic plastid organelle that plays an essential
role in fatty acid metabolism (21). In Toxoplasma, Atg8 tethers the apicoplast to
centrosomes, either directly or indirectly, to ensure proper division of this organelle
during parasite replication (22). In both Toxoplasma and Plasmodium, localization of
Atg8 to the apicoplast is dependent upon its conjugation to PE, highlighting the
importance of a functional Atg8 conjugation pathway in apicomplexan-specific biolog-
ical processes.
The conservation of a functional subset of the autophagy machinery in protozoans
and the parasite-specific roles of the members of this subset suggest that this pathway
may be an ideal target for the development of novel antiparasitics. However, many of
the upstream regulatory proteins targeted by autophagy-manipulating drugs used in
higher eukaryotes are absent or highly divergent in protozoans, rendering these
compounds ineffective (23, 24). Recent structural characterization of Plasmodium fal-
ciparum Atg8 (PfAtg8) identified differences in the electrostatic surface potential and
amino acid composition between PfAtg8 and the human Atg8 homologues LC3 and
GATE-16 (25). These differences were significant enough to result in an 30-fold
preference for the binding of small-molecule inhibitors for PfAtg8 compared to human
LC3 (26). Moreover, high-throughput screens have identified numerous compounds
that inhibit the interaction between recombinant P. falciparum Atg3 (PfAtg3) and
PfAtg8 in vitro, including a group of compounds from the Medicines for Malaria Venture
(MMV) Malaria Box with antimalarial activity in tissue culture (25–27). These findings
illustrate the ability to specifically target the parasite Atg3-Atg8 interaction and suggest
that the Atg3-Atg8 interaction may be an attractive new drug target in apicomplexan
parasites. In addition to serving as novel therapeutics, Atg3-Atg8 interaction inhibitors
would be powerful tools with which to assess the Atg8 function in apicomplexan
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parasite biology. While the results of preliminary studies in Plasmodium are promising,
the utility of these compounds in other apicomplexans has not yet been evaluated.
In this study, three PfAtg3-Atg8 inhibitors were assessed to identify their activities
and mechanisms of action in Toxoplasma. All three inhibitors blocked Toxoplasma
growth in vitro at submicromolar concentrations. Interestingly, treatment with two of
the three compounds induced TgAtg8 lipidation to a similar extent as induction of
autophagy by treatment with monensin or extracellular starvation. Further, we found that
treatment with the third compound resulted in increased levels of intracellular calcium and
the induction of parasite egress from host cells. Together, our results show that the
reported PfAtg3-Atg8 interaction inhibitors are active against Toxoplasma in vitro but are
active through unique and previously unreported mechanisms of action.
RESULTS
Plasmodium Atg8-Atg3 inhibitors impair Toxoplasma replication in vitro. To
determine whether the three PfAtg3-Atg8 interaction inhibitors MMV007907 (MMV1),
MMV001246 (MMV2), and MMV665909 (MMV3) (Table 1) had activity against Toxo-
plasma, parasites were inoculated onto human foreskin fibroblast (HFF) monolayers
and allowed to replicate for 5 days in the presence of either 10 M drug or the dimethyl
sulfoxide (DMSO) vehicle. Treatment with all three MMVs showed a significant reduc-
tion in the area of host cell lysis, suggesting that Toxoplasma progression through the
lytic cycle was impaired by drug treatment (Fig. 1A). This growth inhibition was further
confirmed using an established colorimetric assay (28) that utilizes a Toxoplasma strain
stably expressing the Escherichia coli -galactosidase enzyme to generate quantitative
inhibition curves for MMVs 1 to 3 (Fig. 1B). All three compounds exhibited submicro-
molar 50% effective concentrations (EC50s), in agreement with the range of EC50s
reported for these compounds in P. falciparum and other protozoan parasites (Table 1)
(29–33).
Interestingly, MMVs 1 to 3 were not identified as having activity against Toxoplasma
in a recent high-throughput screen of the Malaria Box compounds (29). To address this
discrepancy and to confirm the validity of our experimental approach, growth inhibi-
tion assays were also conducted using pyrimethamine. From these assays, we obtained
an EC50 of 1,084 nM, in agreement with previously reported EC50s for pyrimethamine
in RH strain parasites (34). Additionally, the activities of MMVs 1 to 3 against Toxoplasma
were further confirmed using parasite doubling assays, which showed that all three
compounds impaired parasite replication in a concentration-dependent manner (Fig.
1C). Together, our results show that all three PfAtg3-Atg8 interaction inhibitors are
active against Toxoplasma, even though they were not identified in a previous screen
of the Malaria Box compounds to have activity against Toxoplasma.
Virtual docking suggests that MMV compounds are unable to bind within
TgAtg8 W- and L-site pockets. Having shown that MMVs 1 to 3 inhibit Toxoplasma
growth, we next sought to determine whether the mechanism of action for these
compounds was conserved between Plasmodium falciparum and Toxoplasma. We first
assessed the conservation of amino acid residues within the W- and L-site binding
pockets between PfAtg8 and TgAtg8, as these regions represent the putative sites for
MMV 1 to 3 binding to PfAtg8 (26). Alignment of the PfAtg8 and TgAtg8 amino acid
sequences showed a high level of conservation (66% identity, 83% similarity), including
17 out of the 19 residues comprising the PfAtg8 W- and L-site binding pockets (Fig. 2A).
This significant level of conservation suggested that MMVs 1 to 3 may bind to TgAtg8
in a manner similar to that reported for PfAtg8.
To test this hypothesis, we modeled the TgAtg8 protein structure using the I-TASSER
server (35) and used the predicted structure for docking analyses with MMVs 1 to 3 (Fig.
2B). In parallel, we performed docking of all three compounds with the solved PfAtg8
crystal structure to confirm that the predictions generated by the docking program
used in our studies (SwissDock) were in agreement with those generated in previous
docking studies that used the OpenEye docking program (26). Interestingly, while all
three compounds were predicted to bind within the W- and L-site pockets in PfAtg8,
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TABLE 1 Reported activity of PfAtg3-Atg8 inhibitors against protozoan pathogensb
aER, early ring; LR, late ring; T, trophozoite; S, schizont; M, merozoite.
bID, accession number; N/A, not available.
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only MMV1 was predicted to bind to this region in TgAtg8 (Fig. 2B). Together, these
results suggest that the ability of the PfAtg3-Atg8 inhibitors to bind within the TgAtg8
W- and L-site pockets may not be conserved, despite the high levels of similarity
between PfAtg8 and TgAtg8 in both amino acid sequence and predicted protein
structure.
MMVs 1 to 3 do not block the lipidation of TgAtg8. Despite these potential
differences in binding, we next sought to experimentally assess whether the activities
of MMVs 1 to 3 in Toxoplasma were attributable to their reported mechanism of action
in inhibiting the Atg3-Atg8 interaction and, thus, preventing Atg8 lipidation. Genetic
manipulation of TgAtg8 lipidation by conditional knockdown of T. gondii Atg3 (TgAtg3)
(14) and T. gondii Atg4 (TgAtg4) (15) resulted in defects in the maintenance of the
mitochondrion and apicoplast organelles. We therefore hypothesized that if the mech-
anism of action for MMVs 1 to 3 was conserved in Toxoplasma, treatment with the MMV
compounds would similarly affect these organelles. Interestingly, while conducting
these assays, we noted that treatment with MMV1 at concentrations greater than 1 M
caused parasite egress from the host cell. This effect was unique to MMV1, as MMV2
and MMV3 did not induce egress at any of the concentrations tested. Therefore, our
characterization of the effects of MMV1 treatment on the mitochondrion and apicoplast
FIG 1 PfAtg3-Atg8 inhibitors block Toxoplasma growth in vitro. (A) Representative results of a plaque
assay showing impaired parasite growth over a 5-day period in the presence of MMV compounds at 10
M compared to the growth of DMSO vehicle-treated controls. (B) Growth inhibition curves were
generated to determine the EC50 of each of the three MMV compounds. Parasites expressing
-galactosidase were cultured in the presence of drug or DMSO for 4 days. Parasite growth was assessed
by colorimetric assay following a 24-h incubation with the -galactosidase substrate CPRG. Percent
inhibition was calculated by normalization to the levels of inhibition for wells with uninfected HFFs (100%
inhibition) and DMSO vehicle-treated infected HFFs (0% inhibition). Curves represent the averages from
three independent experiments and are plotted with error bars, representing SEMs. EC50s were calcu-
lated by nonlinear regression using Prism software, and the EC50 of each compound is included below
the respective curve. (C) After 24 h of treatment with MMVs 1 to 3, the inhibitors showed a concentration-
dependent decrease in the number of parasites per vacuole (indicated in the key) compared to that for
the DMSO vehicle-treated controls. Data represent means  SEMs (n  3).
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was limited to concentrations below 1 M. In contrast, MMV2 and MMV3 were tested
at concentrations up to 10 M, as the effects of PfAtg3-Atg8 inhibitors on PfAtg8
lipidation were observed only at concentrations significantly higher than their observed
EC50s (26).
No alterations in mitochondrial morphology were observed in parasites treated with
MMV2 or MMV3 at 1 M (Fig. 3A), a concentration at which both compounds signifi-
cantly inhibited parasite growth (Fig. 1). However, upon treatment of intracellular
parasites with 10 M MMV2 and MMV3, we observed significant mitochondrial frag-
mentation (Fig. 3A). The effects on the mitochondrion were observed within the first
6 h of treatment (mean  standard error of the mean [SEM] mitochondrial fragmen-
tation, 65.0%  13.0% and 84.7%  8.2% for MMV2 and MMV3, respectively; n  3),
with nearly all vacuoles containing parasites with fragmented mitochondria after 24 h
of treatment (mean  SEM mitochondrial fragmentation, 94.4%  3.2% and 97.7% 
0.7% for MMV2 and MMV3, respectively; n  3) (Fig. 3B). Nonetheless, since this
concentration is significantly higher than the lethal concentrations at which we did not
observe mitochondrial alterations, inhibition of parasite growth by MMV2 and MMV3 is
likely independent of their ability to induce mitochondrial fragmentation. Additionally,
whereas the effects of monensin treatment and starvation on mitochondrial fragmen-
tation were prevented by cotreatment with the autophagy inhibitor 3-methyladenine
(3-MA) (17, 18), no such protection was observed upon cotreatment of MMV2 or MMV3
with 3-MA (Fig. 3A). Unlike the mitochondrion, the apicoplast remained intact under all
FIG 2 P. falciparum Atg3-Atg8 inhibitors are not predicted to bind to TgAtg8, despite the conservation of residues comprising
the W- and L-site pockets. (A) Comparative analysis of the PfAtg8 and TgAtg8 amino acid sequences, highlighting the
conservation of residues in the W site (blue), L site (red), and apicomplexan-specific loop (yellow). Two residues (F48 and L49)
contributing to both the W and L sites are highlighted in purple. Numbers below the sequence alignments indicate the
number of conserved residues in each region. (B) The TgAtg8 protein structure was predicted using the I-TASSER server and
was used for in silico docking studies for MMVs 1 to 3. (Insets) Predicted binding sites for each of the MMV compounds. The
residues located in the W- and L-site binding pockets, as well as the apicomplexan loop, on the protein surface are highlighted
using the coloring scheme described above.
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treatment conditions, although defects in the positioning and segregation of this
organelle into dividing parasites were frequently observed (Fig. 3C, arrowheads). The
mitochondrion and apicoplast were unaffected by treatment with concentrations of
MMV1 that did not induce parasite egress (Fig. 3B and C).
We next sought to directly assess whether treatment with MMVs 1 to 3 altered
TgAtg8 lipidation status. In yeast and mammalian systems, Atg8 lipidation is routinely
monitored by visualization of a GFP-Atg8 fusion protein, which relocalizes to cytosolic
punctae representing autophagosomes following autophagy induction (36). A similar
approach has been used to monitor the induction of Atg8 lipidation in Toxoplasma in
response to drug treatment and starvation (14, 17). However, TgAtg8 also localizes to
the outer membrane of the apicoplast in a lipidation-dependent manner (15). Given the
reported function of MMVs 1 to 3 as Atg3-Atg8 interaction inhibitors, we hypothesized
that treatment of intracellular parasites with MMVs 1 to 3 would result in a loss of
TgAtg8 localization to the apicoplast, as was observed in TgAtg8 mutants lacking the
C-terminal glycine required for lipidation (15). However, we experienced difficulties in
testing this hypothesis due to the high levels of GFP-TgAtg8 present in the cytosol as
the result of its overexpression (14). Thus, to facilitate the monitoring of TgAtg8
FIG 3 Effects of MMV treatment on autophagy-related organelles. (A) Representative IFA images of
parasites treated with DMSO, 10 mM 3-MA, MMV2, or MMV3 for 24 h and stained for the mitochondrial
matrix protein F1-ATPase (red) and with DAPI (blue). Mitochondrial fragmentation was observed with 10
M treatment and was not protected by cotreatment with 3-MA. (B) Representative IFA images following
6 and 24 h of treatment with the DMSO vehicle or MMVs stained for F1-ATPase (red) to visualize the
mitochondrion. (C) Results of IFAs of DMSO- or MMV-treated parasites stained with ATrx1 (red) to visualize
the apicoplast and DAPI (blue). The apicoplast remains intact during MMV treatment; however, organelle
positioning defects are observed at 24 h (arrowheads), likely due to the observed defects in cytokinesis.
Bars  3 m.
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lipidation and localization in response to intracellular MMV treatment, we generated a
parasite strain in which the endogenous TgAtg8 gene was replaced with the TgAtg8
cDNA sequence containing an N-terminal c-Myc epitope tag driven by the endogenous
TgAtg8 promoter (Fig. 4A). Correct integration was confirmed by PCR of the TgAtg8
locus from recovered clones (Fig. 4B). Immunoblotting revealed that, as reported for
endogenous TgAtg8 (14), c-Myc–TgAtg8 migrates as two bands representing cytosolic
and lipidated Atg8 (Atg8-PE) (Fig. 4C). Additionally, immunofluorescence staining
showed that c-Myc–Atg8 correctly localized to the apicoplast, as shown by the colo-
calization of c-Myc–Atg8 with the DAPI (4=,6-diamidino-2-phenylindole)-stained apico-
plast immediately apical of the parasite nucleus (Fig. 4D). These results demonstrate
that endogenously tagged c-Myc–TgAtg8 undergoes lipidation and localization to the
apicoplast in a manner similar to that previously reported for endogenous TgAtg8 and
GFP-TgAtg8 (14).
We next used these parasites to test the hypothesis that treatment with the MMV
compounds would result in a shift in TgAtg8 localization from the apicoplast to the
cytosol. Intracellular parasites were treated for 6 and 24 h with 500 nM MMV1, 1 M
(data not shown) or 10 MMMV2 and MMV3, or DMSO. Under all treatment conditions,
TgAtg8 retained its punctate staining pattern and remained predominantly localized to
the apicoplast (Fig. 5A). Further, immunoblotting revealed that rather than inhibiting
TgAtg8 lipidation, treatment with 10 M MMV2 and MMV3 for 6 h resulted in an
increase in the lipidated form of TgAtg8, similar to the effects of autophagy induction
by starvation and monensin treatment on endogenous TgAtg8 (Fig. 5B).
As before, the induction of egress by MMV1 treatment limited the concentrations of
this compound that we were able to assess to concentrations well below those
reported to affect Atg8 lipidation in Plasmodium falciparum (26). Therefore, we could
not determine whether MMV1 could block TgAtg8 lipidation in intracellular parasites.
To overcome this limitation, we used established methods to monitor GFP-TgAtg8
FIG 4 Generation of the c-Myc–Atg8 parasite strain. (A) Diagram of the construct used to target the TgAtg8 genomic locus for replacement with a c-Myc
epitope-tagged TgAtg8 cDNA sequence. Arrows indicate the primer pairs used to confirm proper integration at the endogenous TgAtg8 locus. The blue primer
pair amplifies a fragment unique to the parental strain, the red pair amplifies a unique fragment in the recombined strain, and the black pair amplifies a 1,791-bp
fragment in the parental strain and a 372-bp fragment in the recombined strain. (B) PCR products from genomic DNA (gDNA) isolated from c-Myc–TgAtg8 and
parental (RH Δhx Δku80) parasites. The blue, red, and black arrows refer to the primer pairs described in panel A. Numbers to the right of the gel are molecular
sizes (in base pairs). (C) Western blot (WB) of lysates from freshly egressed parental RH Δhxgprt Δku80 and c-Myc–TgAtg8 parasites, probed with antibodies
recognizing the c-Myc epitope, and Toxoplasma -tubulin as a loading control. Two bands are observed for c-Myc–TgAtg8 and represent the unmodified (Atg8)
and lipidated (Atg8-PE) forms of TgAtg8. (D) Immunofluorescence assay of c-Myc–TgAtg8 parasites stained with DAPI (blue) and for c-Myc (red), showing that
c-Myc–TgAtg8 localizes predominantly to the apicoplast. Bar  3 m.
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lipidation following induction of autophagy by extracellular starvation and tested
whether MMV1 could prevent the lipidation-dependent relocalization from the cytosol
to punctate structures (14). As shown in Fig. 5C, no reduction of GFP-TgAtg8 punctum
formation was observed by cotreatment with either 1 or 10 M MMV1. Together, these
findings show that the MMV compounds do not inhibit Atg8 lipidation in Toxoplasma
and are unlikely to act as the TgAtg3-TgAtg8 interaction inhibitors reported for
Plasmodium.
MMV2 and MMV3 impair Toxoplasma cytokinesis. Given our results suggesting
that MMVs 1 to 3 do not act as Atg3-Atg8 interaction inhibitors in Toxoplasma, we next
FIG 5 Treatment with MMVs does not alter Atg8 localization at the apicoplast or prevent Atg8 lipidation. (A) Representative
results of IFAs of c-Myc–TgAtg8 parasites after 6 and 24 h of treatment with DMSO or MMVs stained with DAPI (blue) and for
c-Myc (red). c-Myc–TgAtg8 retains its apicoplast localization following MMV treatment. Bars  3 m. (B) Representative
immunoblots of lysates from c-Myc–Atg8 parasites treated for 6 h with DMSO or MMVs. Treatment with 10 M MMV2 and
MMV3 increased the ratio of lipidated TgAtg8 (Atg8-PE) to unlipidated TgAtg8 (Atg8). No change in lipidation state was
observed by treatment with 500 nM MMV1. The increased levels of Atg8-PE were similar to the increase in the level of
endogenous TgAtg8 lipidation in RH Δhxgprt parasites starved extracellularly (HBSS) or treated with 1 ng/ml monensin for
6 h. Blots were probed with anti-c-Myc or anti-TgAtg8 and with anti-SAG1 as a loading control. (C) (Left) Representative IFA
images of GFP-Atg8 parasites before (Control) and after 8 h of extracellular starvation in HBSS. (Right) Cotreatment with MMV1
failed to reduce the number of parasites with GFP-Atg8 punctae. Data represent means  SEMs (n  3). ***, P  0.001.
Bar  3 m.
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sought to examine their mechanisms of action in Toxoplasma. Our initial characteriza-
tion of MMVs 1 to 3 revealed that they blocked progression through the lytic cycle, as
shown by the decreased area of lysis of the host cell monolayer in the presence of drug
(Fig. 1B). Further studies showed that MMVs 1 to 3 impaired parasite replication in
a concentration-dependent manner (Fig. 1C). Strikingly, replication was completely
blocked by treatment with 2.5 M MMV2 or MMV3, as all vacuoles contained two
parasites or less after 24 h of treatment, while 50% of DMSO vehicle-treated vacuoles
contained eight or more parasites (Fig. 1C). Importantly, the effects of MMV2 and MMV3
on replication were observed at concentrations below those found to induce mito-
chondrial fragmentation (Fig. 3C) or TgAtg8 lipidation (Fig. 5B). These results suggest
that MMV2 and MMV3 inhibit parasite replication at low concentrations, while treat-
ment with high concentrations results in mitochondrial fragmentation and the induc-
tion of autophagy.
While characterizing the effects of MMV2 and MMV3 on parasite replication, we
observed that parasites treated with MMV2 and MMV3 at concentrations of 2.5 M
exhibited an abnormal, rounded morphology with a loss of uniform parasite size and
shape (Fig. 6B). Staining with DAPI to visualize the parasite nuclei revealed that the
parasites within these abnormal vacuoles appeared to have nuclei that had duplicated
but failed to properly divide. Together, these changes suggest that the effects of MMV2
FIG 6 MMV2 and MMV3 block Toxoplasma replication and impair cytokinesis. (A) (Left) IFA images of
parasites treated with 10 M MMV2 and MMV3 for 6 h showing representative images of normal
vacuoles (vacuoles treated with DMSO) and abnormal vacuoles observed with MMV2 and MMV3
treatment. Visualization of the nuclei by staining with DAPI revealed that MMV2- and MMV3-treated
parasites contained distorted parasites with apparent defects in nuclear division. (Right) The percentage
of abnormal vacuoles did not increase at between 6 and 24 h of treatment. Data represent means 
SEMs (n  3). (B) Representative IFA images of normal vacuoles (vacuoles treated with DMSO) and
abnormal vacuoles (vacuoles treated with MMV2 or MMV3) stained for IMC3 (red) to visualize the inner
membrane complex of daughter cells and DAPI (blue). MMV-treated parasites display nuclei that are not
surrounded by an IMC3-positive cytoskeleton and IMC3 structures that do not contain nuclei or
apicoplasts, as observed by DAPI staining. Bars  3 m.
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and MMV3 on parasite replication may involve impairment of cytokinesis, as the
phenotypes are similar to those observed in parasites with defects in the late stages of
cell division (37, 38).
Quantification of abnormal vacuoles showed that approximately 40% of the vacu-
oles displayed these morphological abnormalities, and the percentage of abnormal
vacuoles did not increase at between 6 and 24 h of treatment. These replication defects
were further characterized by staining with an antibody against the protein inner
membrane complex 3 (IMC3), a component of the parasite cytoskeleton that, together
with the plasma membrane, comprises the parasite pellicle (39). While the nuclei in
DMSO-treated parasites appeared uniform in size and shape and were correctly seg-
regated into a single IMC3-stained pellicle, parasites treated with MMV2 and MMV3
contained duplicated nuclei surrounded by a single cytoskeleton, as well as IMC3
structures containing no nuclei (Fig. 6B). Together, these results suggest that the
growth-inhibitory effects of MMV2 and MMV3 are a result of a rapid block of Toxo-
plasma replication involving disruption of cell division due to impaired daughter bud
formation and nuclear division.
MMV1 induces egress by inducing calcium release from intracellular stores.We
next sought to characterize the mechanism by which MMV1 induces parasite egress
from the host cells. The induction of egress by MMV1 followed kinetics similar to those
observed upon treatment with 1 M the calcium ionophore A23187, which induces
nearly 100% egress within 2 min (Fig. 7A). To quantitatively assess MMV1-induced
egress, we utilized an established assay to measure the release of lactate dehydroge-
nase (LDH) caused by lysis of the host cells upon parasite egress (40). The induction of
egress by MMV1 was concentration dependent, with the egress EC50 being 1,150 nM
(Fig. 7B).
We next examined whether MMV1 induces egress by a mechanism similar to that for
calcium ionophores, which depends on the calcium-dependent protein kinase T. gondii
CDPK3 (TgCDPK3) (41, 42). Interestingly, MMV1 failed to induce egress in parasites
lacking TgCDPK3 (Fig. 7C), indicating that MMV1 induces egress by a mechanism similar
to that used by calcium ionophores. We therefore hypothesized that treatment of
extracellular parasites with MMV1 would result in the release of intracellular calcium, as
has been shown for ionophores (43). To test this, freshly egressed parasites were loaded
with the calcium indicator dye Fluo-4 acetoxymethyl ester (AM) and the fluorescence
intensities were monitored prior to and immediately following treatment with MMV1,
A23187, or the DMSO vehicle. Treatment with MMV1 resulted in increased Fluo-4 AM
fluorescence, with the kinetics and peak intensities being similar to those obtained by
treatment with A23187 (Fig. 7D). Treatment with the cell-permeant calcium chelator
BAPTA-AM [1,2-bis(o-aminophenoxy)ethane-N,N,N=,N=-tetraacetic acid acetoxym-
ethyl ester] completely blocked the increase in Fluo-4 AM fluorescence in response to
MMV1 treatment (Fig. 7E). Lastly, we assessed whether the effect of prolonged treat-
ment with MMV1 is a recapitulation of the loss of parasite viability observed with
extracellular ionophore treatment, termed ionophore-induced death (44). Indeed, treat-
ment of extracellular parasites with MMV1 for 2 h dramatically reduced parasite
viability, as illustrated by the reduction in growth compared to that of the DMSO-
treated controls, as measured by plaque assay (Fig. 7F). Together, our results suggest
that MMV1-induced egress involves the release of calcium from intracellular stores and
activation of the calcium-mediated signaling pathways that have previously been
implicated in parasite egress.
DISCUSSION
In this study, we assessed three P. falciparum Atg3-Atg8 interaction inhibitors to
determine whether they acted in a similar manner in Toxoplasma gondii. Our results
show that despite high levels of conservation of the proposed binding sites for these
compounds on TgAtg8, these compounds do not block TgAtg8 lipidation. Despite the
lack of a conserved mechanism of action, all three compounds were found to inhibit
Toxoplasma growth in a dose-dependent manner, with EC50s being in the submicro-
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molar range. We identified that two of these compounds (MMV001246 [MMV2] and
MMV665909 [MMV3]) inhibit Toxoplasma replication by disrupting daughter bud for-
mation and nuclear segregation during parasite replication. Additionally, we found that
treatment with the third compound (MMV007907 [MMV1]) resulted in the release of
calcium from the intracellular stores, resulting in parasite egress from the host cell.
Numerous PfAtg3-Atg8 inhibitor compounds have been identified using biophysical
approaches (25–27); however, we chose to focus on MMVs 1 to 3 for the following
FIG 7 MMV1 induces parasite egress by increasing intracellular calcium levels. (A) Infected HFF mono-
layers were treated for 2 min with 10 M MMVs, the DMSO vehicle, or 1 M the calcium ionophore
A23187. The percentage of egressed vacuoles was calculated by scoring at least 100 vacuoles as
intracellular or egressed, Data represent means SEMs (n 3). (B) The induction of egress by MMV1 was
quantitatively assessed to determine an EC50 for egress by measuring the amount of lactate dehydro-
genase (LDH) released from the host cells upon parasite egress. Percent egress was normalized to that
achieved in DMSO-treated (0%) and 10 M MMV1-treated (100%) wells. Data represent means  SEMs
(n  3). CI, confidence interval. (C) Parasites lacking the calcium-dependent protein kinase TgCDPK3 fail
to egress following 2 min of treatment with MMV1. Data represent means SEMs (n 3) ***, P 0.0001.
WT, wild type. (D) Kinetic traces of Fluo-4 AM fluorescence (in relative fluorescence units [RFU]) in
response to A23187 or MMV1. Extracellular parasites were loaded with the calcium indicator dye Fluo-4
AM to measure changes in intracellular calcium concentrations following drug treatment. Baseline
fluorescence was measured for 60 s, at which time the compounds were injected into the wells (indicated
by the arrow). The traces represent the average for three technical replicates, with the shaded areas
representing the standard errors of the means. (E) Change in fluorescence intensity between the final
baseline measurement of the number of relative fluorescence units (60 s) and the first measurement
following injection of compounds (67 s). Parasites treated with the calcium chelator BAPTA-AM showed
no change in intracellular calcium levels following treatment with MMV1. Data represent means  SEMs
(n  3). (F) Representative results of a plaque assay used to assess parasite viability following treatment
of extracellular parasites for 2 h with DMSO or MMV1. Control parasites were added to an HFF monolayer
immediately following manual release from host cells and prior to 2 h of treatment.
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reasons. First, MMV1 is one of the few PfAtg3-Atg8 inhibitors that have been found to
alter PfAtg8 lipidation status when parasites are treated in culture (26). Second, all three
of the compounds tested herein were identified from the Medicines for Malaria Venture
Malaria Box, a collection of 200 drug-like and 200 probe-like molecules that is available
for researchers free of charge. Importantly, MMVs 1 to 3 are active against other
important human parasites, including Cryptosporidium spp., Trypanosoma spp., and
Leishmania spp. (Table 1). Collectively, these pathogens represent a significant disease
burden in humans, and treatment of infections caused by these pathogens is threat-
ened by the development of resistance to the limited number of therapeutics currently
available. Therefore, the activity of MMVs 1 to 3 against multiple protozoans suggested
that disruption of the Atg3-Atg8 interaction in these parasites may represent a poten-
tial avenue for the development of novel broad-spectrum antiparasitics.
To address the possibility of a conserved mechanism of action for MMVs 1 to 3
against organisms other than Plasmodium, we evaluated these compounds for their
ability to similarly disrupt the Atg3-Atg8 interaction in the closely related apicomplexan
Toxoplasma. We hypothesized that the similarity between P. falciparum and Toxoplasma
Atg8 proteins would allow the mechanism of action to be conserved between the two
species. Interestingly, our in silico docking experiments failed to identify the predicted
interactions of MMV2 and MMV3 with the TgAtg8 W- and L-site pockets, suggesting
that these compounds may not bind to TgAtg8 in a fashion similar to that described in
P. falciparum (Fig. 2B). It is possible that the absence of predicted docking at the
conserved binding sites could be due to limitations of the experimental approach that
we used in our study, including using a predicted TgAtg8 structure and performing
docking with a single, rigid TgAtg8 conformation. However, even in the absence of a
more robust docking analysis, the results of our in vitro studies are consistent with the
conclusion that these compounds do not inhibit TgAtg8 lipidation by interfering with
TgAtg8 interactions through the W- and L-site binding pockets. Further, although the
residues that comprise the W- and L-site binding pockets are highly conserved between
PfAtg8 and TgAtg8, it is possible that amino acid substitutions in the residues proximal
to these binding pockets could prevent the binding of these compounds to TgAtg8, as
shown for P. yoelii Atg8 (26). The PfAtg8 W- and L-site pockets targeted by MMVs 1 to
3 were proposed to be ideal targets for small-molecule inhibitors due to the differences
in the structure and electrostatic potential of these pockets from those of human Atg8
homologues (25). However, an additional set of compounds that inhibits the PfAtg3-
Atg8 interaction by binding to the apicomplexan loop structure on PfAtg8 has recently
been identified (27). As this structure is unique to apicomplexan Atg8 proteins, it
provides an additional avenue for targeted disruption of the parasite Atg3-Atg8
interaction while avoiding effects on the host. Whether any of the compounds that
target the PfAtg8 apicomplexan loop have activity against Toxoplasma or other api-
complexans remains untested. However, given the differences in the amino acid
sequence present in this loop in Toxoplasma from the sequence present in this loop in
Plasmodium (Fig. 2A), identification of bona fide TgAtg3-Atg8 inhibitors may require
structural resolution of the TgAtg3-Atg8 interaction and/or the development of bio-
physical screening approaches like those used in P. falciparum.
Our characterization of MMVs 1 to 3 shows that all three compounds inhibit
Toxoplasma at submicromolar concentrations. This is in contrast to the findings of a
previous high-throughput screen that failed to identify any of the three MMVs as
having activity against Toxoplasma (29). However, as noted by other authors (29), the
EC50s of certain 2,4-diamino-quinazoline-based compounds that they observed were
significantly higher than the values reported in a separate study with Toxoplasma (45).
The authors attribute these differences to their use of the TS-4 mutant derived from the
standard RH strain, which could also explain the differences between the activities
observed in their study and activities of MMVs 1 to 3 that we observed. Importantly, the
TS-4 mutants were also less sensitive to pyrimethamine (EC50  3.62 M) than the RH
parasites (EC50  0.9 M) (34), suggesting that the TS-4 strain is less susceptible to a
variety of compounds. Additionally, as shown in Table 1, the EC50s obtained from
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high-throughput screens are highly variable, likely due to differences in the methods
used to assess compound efficacy between studies. In contrast, our study characterized
the effects of MMVs 1 to 3 on multiple aspects of Toxoplasma biology using standard
Toxoplasma strains and assays. Our findings illustrate the importance of using multiple,
independent methodologies for screening and validating the activity of the Malaria Box
compounds across species.
Our studies revealed that inhibition of Toxoplasma by MMV2 and MMV3 involves
impairment of parasite replication, as shown by the changes in parasite morphology
and defects in nuclear segregation into daughter parasites in Fig. 6. Additionally, at
higher concentrations, MMV2 and MMV3 induced fragmentation of the mitochondrion
and increased lipidation of TgAtg8 (Fig. 5), similar to the effects of monensin treatment
and starvation (17, 18). These findings provide further evidence for an autophagic cell
death pathway in Toxoplasma that can be induced in response to various stressors,
including drug treatment. However, unlike monensin and starvation, the autophagy
inhibitor 3-MA did not block the effects of MMV2 and MMV3 on the mitochondrion.
One possible explanation for this observation is that the induction of autophagy may
occur downstream of mitochondrial fragmentation. In this scenario, mitochondrial
disruption could be induced by several stimuli, including some that are blocked by
3-MA’s inhibition of phosphoinositide 3-kinase (PI3K) (including starvation and monen-
sin), as well as others that target the mitochondria through alternative, PI3K-
independent mechanisms (like MMV2 and MMV3). We propose that in the case of
MMV2 and MMV3, autophagy is likely induced following mitochondrial fragmentation,
and the subsequent induction of TgAtg8 lipidation may represent cell death with
autophagy rather than cell death by autophagy (46).
In addition to the novel mechanisms of action identified for MMV2 and MMV3, we
also found that MMV1 can induce parasite egress from the host cells. This effect is
comparable to the activity of the calcium ionophore A23187, and like the A23187-
induced egress, the MMV1-induced egress is dependent on signaling through
TgCDPK3. As shown in Fig. 7D and E, MMV1 triggers the release of calcium from
intracellular stores; however, the exact mechanism by which this occurs remains
unclear. The chemical structure of MMV1 precludes it from coordinating with calcium
ions and transporting them across membranes in a manner similar to that for A23187.
Instead, MMV1 may bind directly to receptors or ion channels to trigger calcium release,
although such receptors and channels remain to be identified in Toxoplasma. Alterna-
tively, MMV1 may act similarly to other small molecules that stimulate calcium release
and parasite egress through activation of the cGMP-dependent protein kinase G (PKG)
signaling pathway (40, 47). Further studies are needed to determine whether the effects
of MMV1 are dependent on PKG signaling and to determine which intracellular stores
release calcium in response to MMV1 treatment.
Together, our studies revealed that MMVs 1 to 3 inhibit Toxoplasma at concentra-
tions below those reported to have cytotoxic effects in human fibroblasts (Table 1) (30,
33). However, it is worth noting that the human cytotoxicity data were obtained from
experiments in which subconfluent MRC-5 fibroblasts were grown for 72 h in the
presence of each compound. As a result, the values obtained from these experiments
could also be attributed to inhibition of cell proliferation by these compounds. Other
studies exploring the cytotoxic effects of MMVs 1 to 3 showed that while MMV1 was
well tolerated, MMV2 and MMV3 displayed cytotoxic effects on zebrafish embryos and
human liver hepatocytes at low micromolar concentrations (30). It is possible that the
inhibitory effects of MMV2 and MMV3 on cell division observed in Toxoplasma are
conserved in higher eukaryotes and contribute to the cytotoxicity of these compounds.
Interestingly, we did not observe any negative effects on HFFs exposed to MMV2 and
MMV3 at 10 M, suggesting that these compounds may be selectively toxic to cells
undergoing active proliferation.
Preliminary pharmacokinetic studies in mice suggest that MMVs 1 to 3 are highly
bound to plasma proteins (95%) (30). Additionally, mice given an oral dose of 140
g/kg of body weight failed to show plasma concentrations greater than 1 M within
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9 h of administration, suggesting that the efficacy of these compounds in vivo may be
limited due to poor bioavailability (30). However, whether these compounds can be
administered at dosages that are efficacious in an in vivo model of toxoplasmosis
remains untested. While MMVs 1 to 3 may currently be limited to use in vitro for target
identification, future structure-activity relationship studies may lead to the develop-
ment of derivatives of these compounds with better pharmacological properties. As
MMVs 1 to 3 already display activity against a variety of protozoan pathogens, further
characterization of their mechanisms of action and identification of their specific targets
hold promise toward the development of compounds for use as broad-spectrum
antiparasitics.
MATERIALS AND METHODS
Chemicals and reagents. The compounds used for the initial screens against Toxoplasma were from
the Malaria Box compound library from the Medicines for Malaria Venture (48–50). For further studies,
MMV007907 (referred to here as MMV1) was obtained from Hit2Lead (compound identification number
5664106), while MMV001246 (MMV2) and MMV665909 (MMV3) were obtained from Enamine Ltd.
(catalogue numbers Z29466516 and Z29467539, respectively). A23187 (Sigma-Aldrich) was dissolved in
DMSO at 1 mM and stored in single-use aliquots at 20°C. The cell-permeant calcium chelator
BAPTA-AM (Sigma-Aldrich) was dissolved in DMSO at 50 mM. The antibodies used in this study included
mouse anti-F1 (1:2,000), mouse anti-c-Myc (1:1,000; clone 9B11; Cell Signaling Technology), mouse
anti-SAG1 (1:2,000; GenWay Biotech), rat anti-IMC3 (1:2,000) (39), mouse anti-ATrx1 (1:2,000) (51), and
rabbit anti-toxoplasma -tubulin (1:2,000) (37). Fluorophore-conjugated secondary antibodies for immu-
nofluorescence assays (IFAs) (Alexa Fluor; Thermo Fisher) were used at 1:2,000 dilutions. Horseradish
peroxidase-conjugated secondary antibodies (GE Healthcare) were used for immunoblotting at 1:2,000
dilutions.
Bioinformatics and modeling of TgAtg8. Amino acid sequence alignments were performed using
the Clustal Omega program (52). To generate a structural model of TgAtg8, the TgAtg8 protein sequence
was provided as input to the I-TASSER online server (35) using default settings and no additional
restraints or templates. Docking simulations were done using the SwissDock server (53, 54), providing the
solved PfAtg8 structure (PDB accession number 4EOY) (25) or the output of the I-TASSER TgAtg8 model
as the input for the target and the ZINC accession numbers for the MMV compounds (Table 1) as the
input for the ligands. All docking was done using the default/accurate specifications and without
defining a region of interest. Docking results were visualized and screened using the ViewDock tool in
the UCSF Chimera program (55, 56).
Parasite culture. Parasites were maintained by serial passage in human foreskin fibroblasts (HFFs) in
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% heat-inactivated fetal bovine
serum (FBS), 1% 100 U/ml penicillin plus 100 g/ml streptomycin (PenStrep), and 2 mM L-glutamine and
incubated at 37°C in 5% CO2. All drug treatment experiments were conducted in DMEM supplemented
with 1% FBS, 1% PenStrep, and 2 mM L-glutamine. The type I RH Δhxgprt parasite strain (57) was used
to assess parasite doubling time, plaque formation, organelle integrity, and intracellular calcium levels in
response to MMV treatment. Egress assays were performed using RH Δhxgprt and TgCDPK3 knockout
parasites generated in the type II Pru Δku80 background strain (58) and the vector and cloning approach
for generation of the type I TgCDPK3 knockout strain described in reference 41. Extracellular starvation
assays were done using RH Δhxgprt parasites ectopically expressing GFP-TgAtg8 (14). Endogenous c-Myc
epitope tagging of TgAtg8 was performed using RH Δhxgprt Δku80 parasites (59).
Assessment of parasite viability in vitro. For plaque assays, 500 syringe-lysed parasites were added
to a confluent HFF monolayer in a 12-well plate and allowed to propagate for 5 days at 37°C in 5% CO2.
For plaque assays assessing the effect of MMV1 treatment on extracellular parasites, parasites were
added to the HFF monolayer immediately upon syringe lysis or following a 2-h incubation in 1% FBS
medium containing MMV1 or the DMSO vehicle. After 5 days of incubation, the cells were fixed with
methanol and stained using crystal violet (Sigma-Aldrich) to observe regions of host cell lysis. To assess
the parasite doubling time, syringe-lysed parasites were inoculated into confluent HFF monolayers in
12-well plates and allowed to invade for 2 h. The monolayers were then washed three times with
medium to remove uninvaded parasites, and medium containing drug or vehicle was added to the wells.
At 24 h postinfection, the cells were fixed with methanol and stained with stain from a Differential Quik
stain kit (Polysciences, Inc.). For each treatment, at least 100 vacuoles from three biological replicates
were assessed for the number of parasites per vacuole. Graphs were generated using Prism software
(v7.0a; GraphPad).
To generate growth inhibition curves to determine the EC50s of the MMV compounds, HFF mono-
layers in 96-well plates were inoculated with 100 syringe-lysed -galactosidase-expressing parasites (28).
At 4 days after inoculation, chlorophenol red--D-galactopyranoside (CPRG) was added to each well at a
final concentration of 100 M. The plates were read 24 h after the addition of CPRG on a Synergy H1
plate reader (BioTek) with excitation at 570 nm and emission at 630 nm. Averages from three biological
replicates were used to generate growth inhibition curves using Prism software, and the results were
normalized to those for wells with uninfected HFFs (100% inhibition) and the dimethyl sulfoxide (DMSO)
vehicle (0% inhibition). Results from three independent replicates were plotted in Prism software, and
curves were fit to the log-transformed (x axis) data by nonlinear regression, using the four-parameter,
variable slope settings.
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Analysis of parasite egress. Freshly lysed parasites were inoculated into confluent HFF monolayers
and allowed to replicate overnight. On the following day, the monolayers were washed with Hanks’
buffered saline solution (HBSS), after which HBSS containing drug or DMSO as a vehicle control was
added to the cells. Following a 2-min incubation at 37°C, the plates were fixed with methanol and stained
with Differential Quik stain. Percent egress was determined by counting at least 100 vacuoles from
biological triplicates under each condition.
Induction of egress by MMV1 was quantitatively measured using a CytoTox-One homogeneous
membrane integrity assay (Promega). This assay measures the amount of lactate dehydrogenase (LDH)
released from host cells as a result of parasite egress (40). Confluent HFF monolayers were infected with
5  104 parasites per well in 96-well format. At 24 h postinfection, the monolayers were washed with
DMEM supplemented with 1% FBS and were incubated in the same medium with drug (MMV1) in a
2-fold serial dilution or vehicle (DMSO), with each treatment being done in technical triplicate. After a
15-min incubation at 37°C, 50 l of CytoTox-One assay buffer with substrate was added to each well and
the plate was incubated for 5 min at 25°C. The reaction was stopped by the addition of 25 l stop
solution to each well, and the plates were read on a plate reader with excitation at 560 nm and emission
at 590 nm. The values were analyzed using Prism software and were normalized to the results obtained
with 10 M MMV1 (100%) inhibition and DMSO (0% inhibition). Results represent averaged values from
three independent biological replicates, and the log-transformed (x axis) data were fit using nonlinear
regression (four parameters, variable slope) to determine EC50s.
Endogenous tagging of TgAtg8. Total RNA from RH Δhxgprt Δku80 parasites was isolated using an
RNeasy minikit (Qiagen), and 2 g of total RNA was reverse transcribed using an Omniscript reverse
transcription kit (Qiagen) to generate cDNA. The TgAtg8 coding sequence (EuPathDB GeneID
TGGT1_254120) was amplified using primers 1 and 2, and primers 3 to 5 were used to introduce an
N-terminal c-Myc epitope tag and overhangs for In-Fusion cloning (see Table S1 in the supplemental
material). Primers 6 to 9 were used to amplify the 5= and 3= homologous sequences from RH Δhxgprt
Δku80 genomic DNA isolated using a DNeasy kit (Qiagen). The SAG1 3=untranslated region (UTR) was
amplified using primers 10 and 11. These fragments were cloned into a modified pBluescript KS()
vector containing the hypoxanthine-xanthine-guanine phosphoribosyltransferase (HXGPRT) selection
cassette using an In-Fusion HD cloning kit (Clontech) to generate the final plasmid depicted in Fig. 4A.
For the generation of c-Myc–Atg8 parasite strains, 100 g of BglI-linearized plasmid DNA was
transfected into freshly lysed RH Δhxgprt Δku80 parasites. Parasites were subjected to selection with 25
g/ml mycophenolic acid with 25 g/ml xanthine for three passages, and surviving parasites were
cloned by limiting dilution into 96-well plates. Single, independent clones were screened for proper
integration by genomic PCR using primers 1, 2, 10, and 12 to 14, and positive clones were confirmed by
immunoblotting and immunofluorescence assays by staining for c-Myc.
Induction of autophagy. To assess TgAtg8 lipidation status in response to drug treatment, confluent
HFF monolayers in T-175 tissue culture flasks were inoculated with 2  107 freshly lysed parasites. At
36 h postinfection, the cells were washed with 1% FBS medium and replaced with 1% FBS medium
containing vehicle or drug. After 6 h, the cells were washed twice with medium to remove extracellular
parasites. Intracellular parasites were then scraped and passed through a 27-gauge needle to release the
parasites from the host cells, and the recovered parasites were washed twice with ice-cold phosphate-
buffered saline (PBS). Assessment of the endogenous TgAtg8 lipidation status in response to extracellular
starvation was done as was described above for the GFP-TgAtg8 starvation experiments, but intracellular
parasites that were manually released from cells prior to HBSS starvation were used.
For the assessment of GFP-TgAtg8 punctum formation, freshly lysed GFP-TgAtg8 parasites were
washed in HBSS and resuspended in HBSS with the DMSO vehicle or drug. The parasites were incubated
for 8 h at 37°C in 5% CO2 and were added to poly-L-lysine-coated coverslips for imaging. At least 100
parasites from three biological replicates were counted.
Immunoblotting. Parasite pellets were lysed for 30 min in cold radioimmunoprecipitation assay
(RIPA) buffer containing 1% sodium deoxycholate and supplemented with a cOmplete Mini protease
inhibitor tablet (Roche), sonicated with a microtip sonicator once for 10 s, and centrifuged for 5 min at
16,000  g to remove insoluble debris. The cleared lysate equivalent of 1  107 parasites per load was
separated on 4 to 20% Mini-Protean TGX gels (Bio-Rad) and transferred to a nitrocellulose membrane for
immunoblotting. Membranes were blocked for 30 min in a solution of 5% milk–Tris-buffered saline with
0.1% Tween 20 (TBST) and probed with primary antibodies overnight at 4°C. Following three 10-min
washes in TBST, secondary antibodies were incubated for 45 min at room temperature in milk-TBST. The
membranes were again washed three times for 10 min each time in TBST, and proteins were detected
with SuperSignal West Femto substrate (Thermo Fisher) and imaged on a FluorChem R imager (Bio-
Techne).
Immunofluorescence assays. For all IFAs, infected HFFs (grown on coverslips) were washed with
PBS, fixed with 4% paraformaldehyde in PBS for 15 min, and washed two additional times with PBS.
The fixed, infected monolayers were then incubated for 30 min with 3% bovine serum albumin
(BSA)–PBS to block and permeabilized for 15 min in BSA–PBS with 0.2% Triton X-100 (PBS-T).
Samples were then incubated overnight with primary antibodies in BSA–PBS-T at 4°C, washed 3
times for 10 min each time with PBS, and incubated in secondary antibodies for 45 min in BSA-PBS.
Coverslips were then washed twice with PBS for 10 min, stained with DAPI (4=,6-diamidino-2-
phenylindole) in PBS for 10 min, and washed two more times with PBS for 10 min. The coverslips
were then mounted using Vectashield antifade mounting medium (Vector Laboratories) and imaged
on a Nikon Eclipse 80i microscope.
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Cytosolic Ca2 measurements. Freshly egressed parasites were passed through a 3-m-pore-size
filter to remove host cell debris and were washed once with intracellular buffer (IB; 5 mm NaCl, 144 mm
KCl, 5.6 mm D-glucose, 1 mm MgCl2, 2 mm EGTA, 25 mm HEPES, pH 7.4). The parasites were then
loaded with 2.5 M Fluo-4 AM calcium indicator dye (Thermo Fisher) with or without 50 M
BAPTA-AM in IB for 1 h at room temperature. Following a 30-min wash with IB to remove
extracellular dye, the parasites were resuspended in IB to a final concentration of 107 parasites per
ml, and 100 l was transferred to each well of a 96-well plate. A Synergy H1 (BioTek) plate reader
was used to monitor the Fluo-4 AM fluorescence at 488-nm excitation and 524-nm emission
wavelengths. Experiments were performed under each treatment condition in triplicate, with
measurements being taken every 7 s. After a 1-min period to establish the baseline fluorescence
levels, 10 l of HBSS (calcium and magnesium free) containing DMSO vehicle, A23187, or MMV1 was
added to each well using the Synergy H1 injectors, and measurements were taken every 5 s for 10
min. Data were analyzed using Prism software, with graphs representing the Fluo4-AM fluorescence
intensities after DMSO subtraction.
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